Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
SARS-CoV-2 pathogenesis
MM Lamers, BL Haagmans - Nature reviews microbiology, 2022 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …
caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …
A guide to immunotherapy for COVID-19
FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …
large body of literature has reported the effect of immune-based therapies in patients with …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 16 September 2022
World Health Organization - 2022 - apps.who.int
As of August 2022, there have been over 572 million confirmed cases of COVID-19 (9). The
pandemic has thus far claimed approximately 6.39 million lives (9). Vaccination is having a …
pandemic has thus far claimed approximately 6.39 million lives (9). Vaccination is having a …
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …
transcription (STAT) transcription factors mediate intracellular signal transduction …
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or …
EW Ely, AV Ramanan, CE Kartman… - The Lancet …, 2022 - thelancet.com
Summary Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown
efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) …
efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) …
Innate immune evasion strategies of SARS-CoV-2
JM Minkoff, B tenOever - Nature Reviews Microbiology, 2023 - nature.com
Abstract SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has been
associated with substantial global morbidity and mortality. Despite a tropism that is largely …
associated with substantial global morbidity and mortality. Despite a tropism that is largely …
Therapeutic advances in COVID-19
N Murakami, R Hayden, T Hills, H Al-Samkari… - Nature Reviews …, 2023 - nature.com
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …
millions of lives. Unlike the early days of the pandemic, when management decisions were …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …